Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Intercept Pharmaceuticals, Inc is a biotechnology business based in the US. Intercept Pharmaceuticals shares (ICPT) are listed on the NASDAQ and all prices are listed in US Dollars. Intercept Pharmaceuticals employs 583 staff and has a trailing 12-month revenue of around USD$283.4 million.
Since the stock market crash in March caused by coronavirus, Intercept Pharmaceuticals's share price has had significant negative movement.
Its last market close was USD$37.55, which is 60.47% down on its pre-crash value of USD$94.99 and 26.68% down on the lowest point reached during the March crash when the shares fell as low as USD$47.57.
If you had bought USD$1,000 worth of Intercept Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$588.30 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$402.16.
|Latest market close||USD$37.55|
|52-week range||USD$32.15 - USD$125|
|50-day moving average||USD$41.1176|
|200-day moving average||USD$59.4416|
|Wall St. target price||USD$67.32|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-10.436|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-18)||0.51%|
|1 month (2020-10-26)||30.20%|
|3 months (2020-08-25)||-24.95%|
|6 months (2020-05-22)||-53.36%|
|1 year (2019-11-25)||-61.02%|
|2 years (2018-11-23)||-66.19%|
|3 years (2017-11-24)||-40.59%|
|5 years (2015-11-25)||-79.56%|
|Revenue TTM||USD$283.4 million|
|Gross profit TTM||USD$247.8 million|
|Return on assets TTM||-25.19%|
|Return on equity TTM||-703.8%|
|Market capitalisation||USD$1.1 billion|
TTM: trailing 12 months
There are currently 6.4 million Intercept Pharmaceuticals shares held short by investors – that's known as Intercept Pharmaceuticals's "short interest". This figure is 16.2% up from 5.5 million last month.
There are a few different ways that this level of interest in shorting Intercept Pharmaceuticals shares can be evaluated.
Intercept Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Intercept Pharmaceuticals shares currently shorted divided by the average quantity of Intercept Pharmaceuticals shares traded daily (recently around 649532.08502024). Intercept Pharmaceuticals's SIR currently stands at 9.88. In other words for every 100,000 Intercept Pharmaceuticals shares traded daily on the market, roughly 9880 shares are currently held short.
However Intercept Pharmaceuticals's short interest can also be evaluated against the total number of Intercept Pharmaceuticals shares, or, against the total number of tradable Intercept Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Intercept Pharmaceuticals's short interest could be expressed as 0.19% of the outstanding shares (for every 100,000 Intercept Pharmaceuticals shares in existence, roughly 190 shares are currently held short) or 0.3085% of the tradable shares (for every 100,000 tradable Intercept Pharmaceuticals shares, roughly 309 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Intercept Pharmaceuticals.
Find out more about how you can short Intercept Pharmaceuticals stock.
We're not expecting Intercept Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Intercept Pharmaceuticals's shares have ranged in value from as little as $32.15 up to $125. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intercept Pharmaceuticals's is 1.6315. This would suggest that Intercept Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. It has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China; and Aralez Pharmaceuticals Canada Inc to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.